- Home
- BLNK vs ACIU Comparison
BLNK vs ACIU Comparison
Compare BLNK & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLNK
- ACIU
- Stock Information
- Founded
- BLNK 2009
- ACIU 2003
- Country
- BLNK United States
- ACIU Switzerland
- Employees
- BLNK N/A
- ACIU N/A
- Industry
- BLNK Industrial Specialties
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- BLNK Consumer Discretionary
- ACIU Health Care
- Exchange
- BLNK Nasdaq
- ACIU Nasdaq
- Market Cap
- BLNK 163.4M
- ACIU 332.4M
- IPO Year
- BLNK N/A
- ACIU 2016
- Fundamental
- Price
- BLNK $1.58
- ACIU $2.71
- Analyst Decision
- BLNK Buy
- ACIU Strong Buy
- Analyst Count
- BLNK 7
- ACIU 2
- Target Price
- BLNK $5.64
- ACIU $12.00
- AVG Volume (30 Days)
- BLNK 4.6M
- ACIU 130.0K
- Earning Date
- BLNK 11-07-2024
- ACIU 11-05-2024
- Dividend Yield
- BLNK N/A
- ACIU N/A
- EPS Growth
- BLNK N/A
- ACIU N/A
- EPS
- BLNK N/A
- ACIU N/A
- Revenue
- BLNK $138,728,000.00
- ACIU $48,505,404.00
- Revenue This Year
- BLNK N/A
- ACIU $85.33
- Revenue Next Year
- BLNK $22.16
- ACIU $80.69
- P/E Ratio
- BLNK N/A
- ACIU N/A
- Revenue Growth
- BLNK 15.13
- ACIU 4097200.00
- 52 Week Low
- BLNK $1.42
- ACIU $2.25
- 52 Week High
- BLNK $3.97
- ACIU $5.14
- Technical
- Relative Strength Index (RSI)
- BLNK 47.86
- ACIU 29.89
- Support Level
- BLNK $1.42
- ACIU $2.62
- Resistance Level
- BLNK $1.54
- ACIU $3.07
- Average True Range (ATR)
- BLNK 0.11
- ACIU 0.15
- MACD
- BLNK 0.00
- ACIU -0.04
- Stochastic Oscillator
- BLNK 37.21
- ACIU 17.24
About BLNK Blink Charging Co.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns majority revenue from U.S.A.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.